On March 19, 2026, Collegium Pharmaceutical, Inc. announced it will acquire AZSTARYS® for $650 million in cash, with potential milestone payments of up to $135 million. This purchase will enhance their ADHD treatment portfolio, marking a significant expansion in their operations.